Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for binding molecules, synuclein, applied in the field of α-synuclein antibody or its antigen-binding fragment or its derivatives
Pending Publication Date: 2022-03-18
AC IMMUNE SA
View PDF21 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
To our knowledge, there are currently no approved or clinically available biomarkers for monitoring pathological α-synuclein levels on the market, despite a critical need for Parkinson's disease research and drug development ( Eberling et al., JParkinsons Dis. 2013;3(4):565-7)
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment Construction
[0930] Preparation of α-synuclein liposome vaccine composition
[0931] Liposome-based antigenic constructs were prepared according to the protocol disclosed in WO2012 / 055933. Liposomal vaccine with human full-length α-synuclein as antigen for antibody production (Table 2, SEQ ID NO: 1) or liposomal vaccine with α-synuclein peptide as antigen for antibody production .
[0932] Table 2: Antigen description
[0933]
[0934] mouse immunization
[0935] Female C57BL / 6JOlaHsd and BALB / cOlaHsd mice (Envigo, USA) were vaccinated at 10 weeks of age. The C57BL / 6JOlaHsd substrain is known to have a spontaneous deletion of the α-synuclein gene. Mice were vaccinated with a vaccine in which synthetic monophosphorylhexayl lipid A 3-deacylated (3D-(6-acyl) ) (Avanti Polar Lipids, USA) containing α-synuclein peptide or human full-length α-synuclein present on the surface of liposomes.
[0936] Mice were vaccinated by subcutaneous injection (s.c.) on days 0, 5, 8, 21, 35, 84 and in ...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The present invention relates to novel molecules useful in the prevention, amelioration, treatment and / or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (a-synuclein, A-synuclein, a-synuclein, A-syn, alpha-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and / or Lewy neurons, such as, but not limited to, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein and Alpha-synuclein. For example, Parkinson's disease, multi-system atrophy, dementia with Lewy bodies (LBD; dementia with Lewy bodies (DLB) ('pure 'dementia with Lewy bodies), dementia with Parkinson's disease (PDD) or diffuse Lewy body disease. The present invention relates to alpha-synuclein binding molecules, in particular alpha-synuclein antibodies or antigen binding fragments or derivatives thereof, and uses thereof. The molecules of the invention may also be used to determine the predisposition of predisposition to such a condition, disease, or abnormality, to monitor a residual condition, disease, or abnormality, or to predict the responsiveness of a patient suffering from such a condition, disease, or abnormality to a treatment with a certain drug.
Description
technical field [0001] The present invention relates to can be used for preventing, alleviating, treating and / or diagnosing and alpha-synuclein (alpha-synuclein, A-synuclein, alpha synuclein, A-syn, alpha-syn, aSyn, a-syn) aggregate-associated diseases, disorders, and abnormalities including, but not limited to, Lewy bodies and / or Lewy neurites, such as Parkinson's disease, multiple Systemic atrophy, Lewy Body dementia (LBD; dementia with Lewy body (DLB) ("pure" dementia with Lewy bodies), Parkinson's disease dementia (PDD)), or diffuse Lewy Physical illness. The present invention relates to α-synuclein binding molecules, especially α-synuclein antibodies or antigen-binding fragments or derivatives thereof and uses thereof. The molecules of the invention can also be used to determine a predisposition to such a condition, disease or disorder, to monitor a residual condition, disease or disorder, or to predict the response to a drug in a patient suffering from such a condition...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more